Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]Pimicotinib in Healthy Male Subjects
NCT06186583Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pimicotinib in tenosynovial giant cell tumor (TGCT), sponsored by Abbisko Therapeutics. Primary endpoints: Cumulative excretion rate of radioactivity in excreta (urine, feces) and total radioactivity, Percentage of each metabolite in urine and feces relative to the administered dose at 1 month and 3 more. Started Dec 2023; status: completed.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT06186583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06186583.